Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
By Elana Gotkine HealthDay Reporter
FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study published online July 21 in JAMA Network Open.
Liam Rose, Ph.D., from the Stanford University School of Medicine in Palo Alto, California, and colleagues conducted a retrospective cohort study to examine OOPCs attributable to initial treatment of common cancers (breast, colorectal, and lung) among privately insured individuals diagnosed at different stages. The cohort included 46,158 patients younger than 65 years, including 19,656 with cancer and 26,502 without cancer (control group). Of those with cancer, 14,581; 2,842; and 2,233 patients had breast, colorectal, and lung cancer, respectively.
The researchers found that an incident cancer diagnosis was associated with a $592.53 per month mean increase in OOPCs for six months after diagnosis. There was a monotonic increase in cost with stage at diagnosis (mean OOPC increase ranged from $462.01 to $719.97 per month for stage 0 and 4, respectively).
"The variability in OOPCs based on cancer stage underscores the need for policies such as paid sick leave, that address both insurance continuity and financial assistance, especially for patients with more advanced cancer," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Autoimmune Diseases Linked to Digestive System Cancers
FRIDAY, Aug. 15, 2025 -- Autoimmune diseases are associated with certain digestive system cancers, according to a review published in the September issue of...
Opportunistic Community Screening IDs Uncontrolled Cardiovascular Risk Factors
FRIDAY, Aug. 15, 2025 -- Opportunistic pop-up community screening identifies a high prevalence of uncontrolled cardiovascular risk factors, according to a study published online...
Missed Opportunity Common in Patients With High-Grade Serous Ovarian Cancer
FRIDAY, Aug. 15, 2025 -- A considerable proportion of patients with high-grade serous cancer (HGSC) have missed opportunities for risk assessment with genetic testing and for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.